摘要
目的:探讨铁死亡基因风险评分和核因子E2相关因子2(Nrf2)与非小细胞肺癌化疗患者预后的关系。方法:选取接受化疗的非小细胞肺癌患者128例,截止2025年6月,最终有72例患者死亡,56例患者存活。比较死亡和存活组患者临床基线资料、铁死亡基因风险评分和Nrf2差异,分析患者预后的影响因素。结果:死亡组肿瘤最大直径≥5 cm、TNM分期Ⅳ期、低分化、有淋巴结转移比例分别为63.89%、66.67%、45.83%和70.83%,高于存活组(均P<0.05);死亡组铁死亡基因风险评分>0.75和Nrf2阳性表达,比例分别为56.94%和61.11%,高于存活组(均P<0.05);铁死亡基因风险评分>0.75患者中位总生存时间为12个月(95%CI:10.64~13.36),明显短于铁死亡基因风险评分≤0.75患者(P<0.05);Nrf2阳性表达患者中位总生存时间为14个月(95%CI:12.59~15.41),明显短于Nrf2阴性表达患者(P<0.05);Cox比例风险分析显示:TNM分期、分化程度、淋巴结转移、铁死亡基因风险评分、Nrf2是患者预后的影响因素(均P<0.05)。结论:铁死亡基因高风险和Nrf2阳性表达非小细胞肺癌患者预后较差,且铁死亡基因风险评分和Nrf2是患者预后的影响因素,临床治疗时应给予关注。
Objective:To explore the relationship between iron death gene risk score and nuclear factor E2 related factor 2(Nrf2)with prognosis in non-small cell lung cancer patients undergoing chemotherapy.Methods:128 non-small cell lung cancer patients who received chemotherapy were selected.As of June 2025,72 patients died and 56 patients survived.The clinical baseline data,iron death gene risk score,and Nrf2 differences between patients in the death and survival groups were compared,and the factors affecting patient prognosis were analyzed.Results:The proportion of tumors with a maximum diameter of≥5 cm,TNM stageⅣ,low differentiation,and lymph node metastasis in the death group were 63.89%,66.67%,45.83%,and 70.83%,respectively,which were higher than those in the survival group(all P<0.05).The proportion of iron death gene risk score>0.75 and Nrf2 positive expression in the death group were 56.94%and 61.11%,respectively,which were higher than those in the survival group(all P<0.05).The median overall survival time of patients with an iron death gene risk score>0.75 was 12 months(95%CI:10.64-13.36),which was significantly shorter than that of patients with an iron death gene risk score≤0.75(P<0.05).The median overall survival time of patients with Nrf2 positive expression was 14 months(95%CI:12.59-15.41),which was significantly shorter than that of patients with Nrf2 negative expression(all P<0.05).Cox proportional hazards analysis showed that TNM staging,differentiation degree,lymph node metastasis,iron death gene risk score,and Nrf2 were prognostic factors for patients(P<0.05).Conclusion:The high-risk group of iron death genes and non-small cell lung cancer patients with Nrf2 positive expression have poor prognosis,and the iron death gene risk score and Nrf2 are influencing factors for patient prognosis,which should be given attention in clinical treatment.
作者
王若男
徐劲松
王定坤
王烨
罗逸
李钦鹏
李圣维
WANG Ruonan;XU Jinsong;WANG Dingkun;WANG Ye;LUO Yi;LI Qinpeng;LI Shengwei(Respiratory Medicine,Joint Logistics Support Force 908 Hospital,Nanchang 330000,China;Internal Medicine-Cardiovascular Department,First Affiliated Hospital of Nanchang University,Nanchang 330006,China)
出处
《陕西医学杂志》
2025年第10期1370-1374,共5页
Shaanxi Medical Journal
基金
江西省卫生健康委员会科技计划项目(SKJP220211623)。
关键词
铁死亡基因风险评分
核因子E2相关因子2
非小细胞肺癌
预后
生存时间
临床治疗
Iron death gene risk score
Nuclear factor E2 related factor 2
Non small cell lung cancer
Prognosis
Time to live
Clinical treatment
